Company Overview

Arvee Laboratories (India) Limited is a specialized chemical manufacturing company incorporated as a private limited company on January 27, 2012, in Ahmedabad, Gujarat. The company subsequently converted to a public limited company on September 19, 2017, and is currently engaged in manufacturing specialized chemicals.

Business Overview

The company operates across three primary product categories: polymer modifiers, contrast media intermediates, and drug intermediates. This diversified portfolio positions Arvee Laboratories as a significant player in India's specialty chemicals sector, catering to multiple industries including pharmaceuticals, polymers, and chemical intermediates.

#### Product Portfolio

- Polymer Modifiers: The company's polymer modifiers product line includes Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt, and 5-Sodiosulfo-Bis-(B-Hydroxyethyl)-Isophthalate. These products are essential components in the polymer industry, used to enhance the properties of various polymer-based materials.

- Contrast Media Intermediates: The contrast media intermediates portfolio comprises 5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, and 3,5-Diamino Benzoic Acid. These intermediates are crucial for the pharmaceutical industry, particularly in the production of contrast agents used in medical imaging.

- Drug Intermediates: The drug intermediates segment includes 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine, and 2-Chloro-5-Nitrobenzoic Acid. These compounds serve as building blocks for various pharmaceutical formulations.

Financial Performance and Market Position

The company currently has a market capitalization of ₹166 crores and generates revenue of ₹38.5 crores with a profit of ₹2.15 crores. Arvee Laboratories has an operating revenue of ₹38.18 crores on a trailing 12-month basis. However, the company faces challenges with an annual revenue de-growth of -51%, though it maintains a pre-tax margin of 6% and ROE of 3%.

Key Financial Metrics (Latest Available)

- EBITDA: ₹36.11 million INR with an EBITDA margin of 9.38%

- Net Income (Latest Quarter): ₹692,000 INR

- Debt to Equity Ratio: 3% (indicating a healthy balance sheet)

- Market Capitalization: ₹166 Crore

- Promoter Holding: 73.50% (as of March 2025)

- Revenue (TTM): ₹38.18 Crore

- Profit (TTM): ₹2.15 Crore

- Annual Revenue De-growth: -51%

- Pre-Tax Margin: 6%

- ROE: 3%

On May 9, 2025, the company approved its audited financial results for FY25 with an unmodified opinion and re-appointed internal and secretarial auditors.

Market Position and Valuation

The stock is currently trading at approximately 5.29 times its book value. The current PE ratio stands at 75.01, while the PB ratio is 5.51.

- All-Time High: ₹315.00 (April 12, 2024)

- All-Time Low: ₹43.55 (March 22, 2021)

- 52-Week High: ₹235.79

- 52-Week Low: ₹126.54

Corporate Governance and Management

Promoter holding in Arvee Laboratories has remained stable at 73.50% as of March 2025. Since April 1, 2013, the control and management have been completely taken over by Mr. Shalin Sudhakarbhai Patel and Mr. Shalin Bharat Chokshi. Shalin Sudhakarbhai Patel serves as the Chairman and Managing Director of the company.

Dividend Policy

Though the company is reporting repeated profits, it is not paying out dividends. Currently, Arvee doesn't pay any dividends to its shareholders. This retention strategy suggests the company is focusing on reinvesting profits for future growth and expansion.

Manufacturing Infrastructure

The company started construction of its first plant for Thiophene Derivatives in 2013. The manufacturing operations are strategically located to serve both domestic and international markets efficiently. The registered office is located at 49/3 B Shyamal Row House, 100 Feet Road Satellite, Ahmedabad, Gujarat.

Investment Considerations

The company operates in the specialty chemicals sector, which offers significant growth potential driven by increasing demand from pharmaceuticals and other end-user industries. However, investors should note the recent revenue decline of 51% year-over-year, which requires improvement. The company's focus on high-value specialty chemicals and its established product portfolio in critical pharmaceutical intermediates provide a foundation for future growth.

The healthy balance sheet with a reasonable debt-to-equity ratio of 3% signals financial stability. The company's position in the specialty chemicals market, particularly in pharmaceutical intermediates, aligns well with India's growing pharmaceutical industry and the global trend toward outsourcing of chemical manufacturing to India.